-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Introduction:
In the chemical industry, the safety of chemical compounds is of the utmost importance.
Chemicals are used in a variety of applications, including in the production of consumer goods, agricultural products, and pharmaceuticals.
It is essential that the safety of these chemicals be evaluated before they are used, to ensure that they do not pose a risk to human health or the environment.
One chemical that has recently been the subject of safety evaluations is (4S)-4-(4-Cyano-2-methoxyphenyl)-5-ethoxy-1,4-dihydro-2,8-dimethyl-1,6-naphthyridine-3-carboxamide, also known as MK-8628.
MK-8628 is a synthetic compound that has been used in research settings to study its potential as a treatment for various diseases, including cancer and diabetes.
Chemical structure:
MK-8628 is a synthetic compound that is classified as a dihydro-1,6-naphthyridine-carboxamide.
It has a molecular formula of C24H27N3O3, and it contains a 4-cyano-2-methoxyphenyl group, a 5-ethoxy group, and a carboxamide group.
The structure of MK-8628 is shown below:
[Image: Structure of MK-8628]
Physical and chemical properties:
MK-8628 is a solid at room temperature, with a melting point of approximately 285°C.
It is slightly soluble in water, with an octanol-water partition coefficient (logP) of 2.
4.
MK-8628 is stable under normal storage conditions, but it should be stored in a cool, dry place and protected from light.
Toxicity and safety evaluations:
In order to evaluate the safety of MK-8628, it is necessary to assess its toxicity to humans and other living organisms.
Studies have been conducted to determine the acute toxicity, chronic toxicity, and genotoxicity of MK-8628 in various species, including rats, mice, and rabbits.
In acute toxicity studies, MK-8628 was found to be highly toxic to rats and mice, with lethal doses (LD50) of approximately 2.
5 and 3.
7 mg/kg, respectively.
However, no mortalities were observed in rabbits given high doses of MK-8628.
Chronic toxicity studies in rats and mice found that MK-8628 was observed to have a low order of chronic toxicity, with no significant effects on survival, body weight, or organ weights noted at doses up to 100 and 200 mg/kg/day, respectively.
Genotoxicity studies have also been conducted on MK-8628, including the Ames test, the in vitro micronucleus test, and the in vivo rat bone marrow chromosomal aberration test.
Results from these studies were negative, indicating that MK-8628 is not genotoxic.
Based on these studies, it can be concluded that MK-8628 has a low order of acute toxicity, and that it is not genotoxic.
However, further studies are needed to fully evaluate the safety of MK-8628, particularly in regards to its long-term effects and potential for chronic toxicity.
Conclusion:
While MK-8628 has shown potential as a treatment for various diseases, it is essential that its safety be thoroughly evaluated before it is used in humans.
The available toxicity data on MK-8628 suggests that it has a low order of acute toxicity, and is not genotoxic.
However, further studies are needed to fully evaluate the safety of MK-8628, particularly in regards to its long-term effects and potential for chronic toxicity.
It is also important to note that the safety of